Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Andrea Marcellus said there are some foods can can work as a natural Ozempic because they're filled with nutrients that can ...

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for ...

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Massachusetts' largest commercial health insurer is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for ...

Eli Lilly and Company announced on Friday positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy ...

The drugmaker Eli Lilly this week said that tests of its GLP-1 pill could work just as well as injectable drugs like ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.